A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0

作者：

Yuan, Li

Shu, Pei

Li, Xiaoyu

Li, Guiling

Zhang, Keqiang

Lai, Lin

Hong, Jinsheng

Huang, Chu-Ying

Wang, Yongsheng

Xie, Hui

Zheng, Li

Zhou, Qi

机构：

[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China

[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China

[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[4] Hunan Canc Hosp, Changsha, Peoples R China

[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China

[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China

[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5509

引用

页数：1

共 50 条

[31] Phase I/II study of CTLA-4 inhibitor AGEN1884 1 PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors [J].

Coward, J. ;

Lemech, C. ;

Meniawy, T. ;

Dupont, C. D. ;

Gonzalez, A. M. ;

Lim, M. ;

Savitsky, D. ;

Carini, M. ;

Hu, S. ;

Shebanova, O. ;

Dow, E. ;

Ortuzar, W. ;

Buell, J. S. ;

Stein, R. B. ;

Youssoufian, H. .

ANNALS OF ONCOLOGY, 2018, 29 :417-417

[32] A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors [J].

de Braud, Filippo ;

Machiels, Jean-Pascal H. ;

Boggiani, Daniela ;

Rottey, Sylvie W. H. ;

Duca, Matteo ;

Laruelle, Marie ;

Salvagni, Stefania ;

Damian, Silvia ;

Lapeire, Lore D. F. ;

Tiseo, Marcello ;

Dermine, Alexandre ;

Ould-Kaci, Mahmoud ;

Braunger, Juergen ;

Rascher, Juliane ;

Fischer, Daniela ;

Hoefler, Josef ;

Mariani, Gabriella L. ;

Cresta, Sara .

CANCERS, 2020, 12 (06)

[33] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor [J].

Matthew R Janes ;

Jose J Limon ;

Lomon So ;

Jing Chen ;

Raymond J Lim ;

Melissa A Chavez ;

Collin Vu ;

Michael B Lilly ;

Sharmila Mallya ;

S Tiong Ong ;

Marina Konopleva ;

Michael B Martin ;

Pingda Ren ;

Yi Liu ;

Christian Rommel ;

David A Fruman .

Nature Medicine, 2010, 16 :205-213

[34] A retrospective study of toripalimab combined with concurrent chemoradiotherapy in patients with recurrent/advanced cervical cancer [J].

Song, Y. ;

Wang, C. ;

Li, X. ;

Li, Y. ;

Zhang, C. .

ANNALS OF ONCOLOGY, 2021, 32 :S755-S755

[35] A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors [J].

Falchook, Gerald S. ;

Sachdev, Jasgit ;

Imedio, Esteban Rodrigo ;

Kumar, Sanjeev ;

Mugundu, Ganesh ;

Chmielecki, Juliann ;

Jones, Suzanne ;

Spigel, David R. ;

Johnson, Melissa .

CANCER RESEARCH, 2019, 79 (13)

[36] Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH) [J].

Qin, Shukui ;

Lin, Xiaoyan ;

Meng, Zhiqaing ;

Ren, Zhenggang ;

Bai, Yuxian ;

Gu, Shanzhi ;

Zheng, Li ;

Li, Qiu ;

Oh, Sun-Yong ;

Guo, Yabing ;

Kang, Yoong-Koo ;

Kao, Wei-Yu ;

Li, Wei ;

Yoon, Jung-Hwan ;

Zhang, Helong ;

Chen, Pei-Jer ;

Yang, Tsai-Sheng ;

Heo, Jeong ;

Zheng, Zhendong ;

Xie, Hui ;

Yu, Zhinuan .

CANCER RESEARCH, 2023, 83 (08)

[37] TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies [J].

Burris, Howard A., III ;

Kurkjian, C. D. ;

Hart, L. ;

Pant, S. ;

Murphy, P. B. ;

Jones, S. F. ;

Neuwirth, R. ;

Patel, C. G. ;

Zohren, F. ;

Infante, J. R. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) :261-273

[38] ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer [J].

Kamath, Suneel ;

Tai, David ;

Moreno, Irene ;

Babiker, Hani ;

Jin, Zhaohui ;

Yoo, Changhoon ;

Ricard, Fabien ;

Jen, Kai Yu ;

Coward, Jim ;

Liu, Jia ;

Opdam, Frans ;

Millward, Michael ;

Ponz-Sarvise, Mariano ;

Yachnin, Jeffrey ;

Kim, Richard ;

Park, Joon Oh ;

Subbiah, Vivek ;

Schram, Alison M. .

CANCER RESEARCH, 2023, 83 (05)

[39] Development of a Practical Synthesis of a TORC1/2 Inhibitor: A Scalable Application of Memory of Chirality [J].

Hicks, Frederick ;

Hou, Yongquan ;

Langston, Marianne ;

McCarron, Ashley ;

O'Brien, Erin ;

Ito, Tatsuya ;

Ma, Chunrong ;

Matthews, Chris ;

O'Bryan, Colin ;

Provencal, David ;

Zhao, Yuxin ;

Huang, Jie ;

Yang, Qiang ;

Li Heyang ;

Johnson, Matthew ;

Yan Sitang ;

Liu Yuqiang .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (05) :829-837

[40] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor [J].

Janes, Matthew R. ;

Limon, Jose J. ;

So, Lomon ;

Chen, Jing ;

Lim, Raymond J. ;

Chavez, Melissa A. ;

Vu, Collin ;

Lilly, Michael B. ;

Mallya, Sharmila ;

Ong, S. Tiong ;

Konopleva, Marina ;

Martin, Michael B. ;

Ren, Pingda ;

Liu, Yi ;

Rommel, Christian ;

Fruman, David A. .

NATURE MEDICINE, 2010, 16 (02) :205-U115

← 1 2 3 4 5 →